Core Viewpoint - GSK's RSV vaccine, Arexvy, has received backing from a panel of the European Medicines Agency for use in all adults over the age of 18, indicating a significant step towards broader vaccine availability [1] Group 1 - The European Medicines Agency's panel supports the use of Arexvy for adults aged 18 and older, which may enhance GSK's market position in the respiratory vaccine sector [1] - This endorsement could lead to increased sales and revenue opportunities for GSK as the demand for respiratory vaccines rises [1]